Visara appoints ophthalmology leaders to advance VIS-101 drug program

NovaBridge Biosciences (NASDAQ: NBP) announced that its subsidiary Visara has appointed Cadmus C. Rich as Chief Medical Officer and Carlos Quezada-Ruiz as Chairman of its Scientific Advisory Board to oversee development of VIS-101, a drug candidate for eye diseases.

Rich will oversee clinical functions and programs for Visara. He previously served as Chief Medical Officer at Lassen Therapeutics and Aura Biosciences (NASDAQ: AURA), and held positions at IQVIA and Alcon. Rich participated in development of over 40 drug and device programs and led or participated in more than 125 clinical trials.

Quezada-Ruiz will chair Visara's newly formed Scientific Advisory Board. He serves as Assistant Professor of Ophthalmology at Instituto de Oftalmología Fundación Conde de Valenciana in Mexico City and previously held senior roles at Genentech/Roche and 4D Molecular Therapeutics (NASDAQ: FDMT). At Genentech, he contributed to global development and approvals of VABYSMO and SUSIVMO.

VIS-101 is a bifunctional biologic targeting VEGF-A and ANG-2 for treatment of wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. The drug has completed initial safety studies in the United States and China and is currently in a Phase 2 study in China. Visara expects VIS-101 to be ready for Phase 3 trials in 2026.

NovaBridge is the majority shareholder of Visara, which controls global rights to VIS-101 outside of Greater China and certain Asian countries. The information is based on a company press release.

You May Also Be Interested In